{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:57Z","timestamp":1790753817396,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Treatment of chronic hepatitis B (CHB) patients with nucleos(t)ide analogs (NAs) suppresses hepatitis B virus (HBV) DNA synthesis but does not affect synthesis of HBV pregenomic RNA (pgRNA). Hepatitis B virus pgRNA is detectable in the serum during NA treatment and has been proposed as a marker of HBV covalently closed circular DNA activity within the infected hepatocyte. We developed an automated assay for the quantification of serum HBV pgRNA using a dual\u2010target real\u2010time quantitative PCR approach on the Abbott<jats:italic toggle=\"yes\">m<\/jats:italic>2000<jats:italic toggle=\"yes\">sp\/rt<\/jats:italic>system. We demonstrate accurate detection and quantification of serum HBV RNA. Hepatitis B virus DNA was quantified using the Abbott RealTi<jats:italic toggle=\"yes\">m<\/jats:italic>e HBV viral load assay. We further compared serum nucleic acid levels and kinetics in HBV\u2010positive populations. Samples included on\u2010therapy CHB samples (n\u2009=\u200916), samples (n\u2009=\u200989) from 10 treatment na\u00efve CHB subjects receiving 12 weeks of NA treatment with 8\u2010week follow\u2010up, hepatitis B surface antigen\u2013positive blood donor samples (n\u2009=\u2009102), and three seroconversion series from plasmapheresis donors (n\u2009=\u200979 samples).<jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: During NA treatment of CHB subjects, we observed low correlation of HBV DNA to pgRNA levels; pgRNA concentration was generally higher than HBV DNA concentrations. In contrast, when NA treatment was absent we observed serum pgRNA at concentrations that correlated to HBV DNA and were approximately 2 log lower than HBV DNA. Importantly, we observe this trend in untreated subject samples from both chronic infections and throughout seroconversion during acute infection. Results demonstrate that the presence of pgRNA in serum is part of the HBV lifecycle; constant relative detection of pgRNA and HBV DNA in the serum is suggestive of a linked mechanism for egress for HBV DNA or pgRNA containing virions.<\/jats:p>","DOI":"10.1002\/hep.30082","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T16:59:08Z","timestamp":1525712348000},"page":"2106-2117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":152,"title":["Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog\u2010Treated or Untreated Patients During Chronic and Acute Infection"],"prefix":"10.1097","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-0595","authenticated-orcid":false,"given":"Emily K.","family":"Butler","sequence":"first","affiliation":[{"name":"Abbott Laboratories,Abbott Park,Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gersch","sequence":"additional","affiliation":[{"name":"Abbott Laboratories,Abbott Park,Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"McNamara","sequence":"additional","affiliation":[{"name":"Abbott Laboratories,Abbott Park,Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka\u2010Cheung","family":"Luk","sequence":"additional","affiliation":[{"name":"Abbott Laboratories,Abbott Park,Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Holzmayer","sequence":"additional","affiliation":[{"name":"Abbott Laboratories,Abbott Park,Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de Medina","sequence":"additional","affiliation":[{"name":"Schiff Center for Liver Diseases, University of Miami School of Medicine,Miami,Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Schiff","sequence":"additional","affiliation":[{"name":"Schiff Center for Liver Diseases, University of Miami School of Medicine,Miami,Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kuhns","sequence":"additional","affiliation":[{"name":"Abbott Laboratories,Abbott Park,Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin A.","family":"Cloherty","sequence":"additional","affiliation":[{"name":"Abbott Laboratories,Abbott Park,Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"key":"hep30082-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: New estimates of age\u2010specific HBsAg seroprevalence and endemicity","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"hep30082-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"hep30082-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"hep30082-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","year":"2004","journal-title":"J Viral Hepatitis"},{"key":"hep30082-bib-0005-20241017","first-page":"9","article-title":"RNAi\u2010based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","year":"2017","journal-title":"Sci Transl Med"},{"key":"hep30082-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0966-842X(97)01141-4","article-title":"Why are hepadnaviruses DNA and not RNA viruses?","volume":"5","year":"1997","journal-title":"Trends Microbiol"},{"key":"hep30082-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/liv.13001","article-title":"Clinical relevance of the study of hepatitis B virus covalently closed circular DNA","volume":"36","year":"2016","journal-title":"Liver Int"},{"key":"hep30082-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep30082-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta\u2010analysis","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep30082-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.25937","article-title":"Prevention of hepatitis B virus\u2013related hepatocellular carcinoma with antiviral therapy","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep30082-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JCM.00760-17","article-title":"Serum HBV DNA, RNA and HBsAg: which correlated better to intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?","volume":"55","year":"2017","journal-title":"J Clin Microbiol"},{"key":"hep30082-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep30082-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon Alfa\u20102a and nucleos(t)ide analogues","volume":"213","year":"2016","journal-title":"J Infect Dis"},{"key":"hep30082-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep30082-bib-0015-20241017","first-page":"197","article-title":"Detectability and clinical significance of serum hepatitis B virus ribonucleic acid","volume":"4","year":"2015","journal-title":"Hepatobiliary Surg Nutr"},{"key":"hep30082-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","year":"2013","journal-title":"J Gastroenterol"},{"key":"hep30082-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00535-006-1856-4","article-title":"Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy","volume":"41","year":"2006","journal-title":"J Gastroenterol"},{"key":"hep30082-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3851\/IMP1508","article-title":"Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B","volume":"15","year":"2010","journal-title":"Antivir Ther"},{"key":"hep30082-bib-0019-20241017","article-title":"Relationship between serum HBV\u2010RNA levels and intrahepatic viral as well as histologic activity markers in entecavir\u2010treated patients","year":"2017","journal-title":"J Hepatol"},{"key":"hep30082-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"327A","DOI":"10.1016\/0270-9139(95)95032-X","article-title":"HBV marker kinetics during therapy of chronic heptatis B: comparing interferon (IFN) and lamivudine (3TC). [Abstract]","volume":"22","year":"1995","journal-title":"Hepatology"},{"key":"hep30082-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199512213332501","article-title":"A preliminary trial of lamivudine for chronic hepatitis B infection","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"hep30082-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Understanding Bland Altman analysis","volume":"25","year":"2015","journal-title":"Biochem Med"},{"key":"hep30082-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep30082-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep30082-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep30082-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.510230303","article-title":"Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus","volume":"23","year":"1996","journal-title":"Hepatology"},{"key":"hep30082-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2016.10.034","article-title":"Reply to: \u201cSerum HBV pgRNA as a clinical marker for cccDNA activity\u201d: consistent loss of serum HBV RNA might predict the \u201cpara\u2010functional cure\u201d of chronic hepatitis B","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep30082-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian\u2010Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","year":"2016","journal-title":"Hepatol Int"},{"key":"hep30082-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bpg.2017.04.012","article-title":"Current treatment guidelines of chronic hepatitis B: the role of nucleos(t)ide analogues and peginterferon","volume":"31","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201812000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:59:22Z","timestamp":1751619562000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201812000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30082","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"2018-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}